Adding local ablative therapy to EGFR inhibitors linked to longer survival in oligometastatic NSCLC

Design

Systematic review and meta-analysis, largely observational studies

Population

1,077 patients with EGFR-mutated oligometastatic NSCLC, nine studies

Primary outcome

Overall and progression-free survival

Effect

OS HR 0.50 (95% CI 0.42–0.59); PFS HR 0.44 (0.34–0.58)

A meta-analysis pooled nine studies with 1,077 patients with EGFR-mutated, oligometastatic non-small cell lung cancer, comparing first-line tyrosine kinase inhibitor alone with TKI plus local ablative therapy, mostly radiotherapy, to the primary and metastatic sites.

Adding local therapy was associated with longer overall survival (HR 0.50) and progression-free survival (HR 0.44) over a mean follow-up of 29 months, with no significant increase in toxicity. The benefit appeared strongest when local therapy was given as consolidation after initial response.

Most of the included studies were observational, where patients chosen for local therapy are typically fitter with lower disease burden, which inflates apparent benefit. Randomised data, such as the SINDAS trial, have pointed the same way but are limited. This supports discussing consolidative radiotherapy at a tumour board for selected patients with few metastases, rather than routine use.

• Discuss consolidative local therapy at a tumour board for EGFR-mutated patients with limited metastases responding to a TKI.
• Define oligometastatic disease with full staging, including brain MRI and PET-CT where available.
• Consider stereotactic radiotherapy to residual sites after the initial TKI response.
• Watch for pneumonitis when combining thoracic radiotherapy with TKIs.

Why it matters

Local therapy may delay resistance in patients whose disease is limited enough to treat at every site.

Don't overread it

Mostly observational data; the size of benefit is likely overstated by patient selection.

The statistics, in plain English

Hazard ratios of 0.50 and 0.44 suggest large benefits, but in observational studies selection bias can produce effects of this size. The numbers indicate direction more reliably than magnitude.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.